Medscape Editor-in-Chief Eric J. Topol, MD, talks with Siddhartha Mukherjee, MD, PhD, about his career as a researcher and doctor, winning the Pulitzer Prize, and the topic for his next book.

Men younger than 65 years and those with intermediate-risk prostate cancer may benefit most from radical prostatectomy, reports Dr. Gerald Chodak.

What will physician and patient interactions look like in the near future? Medscape Editor-in-Chief Eric Topol, MD, talks about how technology is changing the practice of medicine.

Should clinicians offer parenteral nutrition to cachectic cancer patients who are unable to eat? Dr. David Kerr reports on a study that provides important evidence for this controversial issue.

What code of conduct applies to a physician who becomes a politician, journalist, or TV personality hawking medical miracles?

Dr. Gerald Chodak discusses a recent article by Andrew Vickers and colleagues that could improve the benefit/harm ratio in screening for prostate cancer.

Is it time to rethink the use of some of medicine's most time-honored instruments? Medscape's Eric J. Topol questions the value of 2 well-known icons of medicine.

Dr. John Marshall found board certification 'really hard,' partly because questions had no right answer. He asks: Are boards a fair measure of a practicing physician's skills and knowledge base?

Liquid biopsy may detect cancer recurrence, changes in the tumor, and development of drug resistance -- eventually, says Dr. George Lundberg. But for now, patients and physicians should be wary.

Dr. Kathy Miller talks about John Cleland, who at age 23 with metastatic testis cancer enrolled in the first cisplatin-based trial in 1974, knowing that the investigational drug might offer him no benefit.